Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation

@article{Okamoto2011Abstract1T,
  title={Abstract 1731: TAK-701, a humanized monoclonal antibody to HGF, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with anEGFRmutation},
  author={W. Okamoto and I. Okamoto and K. Tanaka and T. Arao and K. Nishio and M. Fukuoka and P. J{\"a}nne and K. Nakagawa},
  journal={Cancer Research},
  year={2011},
  volume={71},
  pages={1731-1731}
}
  • W. Okamoto, I. Okamoto, +5 authors K. Nakagawa
  • Published 2011
  • Medicine
  • Cancer Research
  • Most non-small cell lung cancer (NSCLC) tumors with an activating mutation of the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib but ultimately develop resistance to these drugs. Hepatocyte growth factor (HGF) induces EGFR-TKI resistance in NSCLC cells with such a mutation. We investigated strategies to overcome gefitinib resistance induced by HGF. Human NSCLC cells with an activating EGFR mutation (HCC827 cells) were… CONTINUE READING
    1 Citations